循環器ジャーナル71巻2号

2023年04月発行

特集 今だからこそ聞きたい心不全診療のこと。 Ⅲ．治療

心不全研究のプール解析で注意すべき点—LVEF spectrumって何？

著者： 白石泰之¹

所属機関： ¹慶應義塾大学医学部循環器内科

ページ範囲：P.252 - P.258

POINT
・複数の試験を集めたプール解析は，データが増えることで検出力が上がり，より信頼度の高い結果を得ることができる．
・特定の解析集団での治療効果などを見るためには，各集団での被験者数・イベント数が十分確保されていることがポイントとなる．

参考文献

1）Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 2014 ; 384 : 2235-43.

2）Cleland JGF, Bunting KV, Flathr MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction : an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018 ; 39 : 26-35.

3）McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 ; 371 : 993-1004.

4）Solomon SD, McMurray JJV, Anand AS, et al. Angiotensin-Neprilysin Inhibition in Heart failure with Preserved Ejection Fraction. N Engl J Med 2019 ; 381 : 1609-20.

5）Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation 2020 ; 141 : 352-61.

6）Bozkurt B, Ezekowitz J. Substance and Substrate : LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials. Circulation 2020 ; 141 : 362-6.

7）Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction : Th PARALLAX Randomized Clinical Trial. JAMA 2021 ; 326 : 1919-29.

8）McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019 ; 381 : 1995-2008.

9）Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022 ; 387 : 1089-98.

10）Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020 ; 383 : 1413-24.

11）Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021 ; 385 : 1451-61.

12）Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure : a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022 ; 28 : 1956-64.

13）Butler J, Packer M, Filippatos G, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 2022 ; 43 : 416-26.

14）Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 2021 ; 384 : 117-28.

15）Vaduganathan M, Docherty K, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure : a comprehensive meta-analysis of five randomized controlled trials. Lancet 2022 ; 400 : 757-67.